Bicycle Therapeutics (United Kingdom)

Recent papers from Bicycle Therapeutics (United Kingdom)

1. Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners FoundationESMO Open · 2026
2. The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugatesExpert Opinion on Investigational Drugs · 2026
3. Zelenectide pevedotin (BT8009) monotherapy in previously treated metastatic urothelial carcinoma (mUC): Update on Duravelo-1.Journal of Clinical Oncology · 2026
4. Zelenectide pevedotin (BT8009) plus pembrolizumab in 1L cisplatin-ineligible locally advanced/metastatic urothelial carcinoma: Update on Duravelo-1 B7.Journal of Clinical Oncology · 2026
5. Abstract LB012: EphA2 expression across molecular and histological subtypes in muscle-invasive bladder cancer (MIBC) and its association with Nectin-4 and HER2Cancer Research · 2026
6. Abstract CT063: An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: Results from a Phase 1/2 studyCancer Research · 2026
7. Abstract 1616: CLSP-5282, a first-in-class T cell engager targeting KRasG12V mutant peptide presented on HLA-A*03:01Cancer Research · 2026
8. Abstract 1325: Preclinical assessment of BT5528 anti-tumor activity in cell-line-derived xenograft (CDX) models of head and neck squamous cell carcinoma (HNSCC).Cancer Research · 2026
9. Abstract 6520: Development and first clinical experiences of a phage display derived bicyclic peptide for EphA2-specific PET imagingCancer Research · 2026
10. Abstract 7227: NECTIN4-a mplified breast cancer targeted by Zelenectide Pevedotin: Amplification and expression are frequent, concordant, and stableCancer Research · 2026
11. Abstract 4518: Preclinical assessment of BT5528 anti-tumor activity in patient-derived xenograft (PDX) models of pancreatic ductal adenocarcinoma (PDAC).Cancer Research · 2026
12. 146TiP A phase II study of zelenectide pevedotin, a Bicycle Drug Conjugate, in patients with NECTIN4 amplified advanced/metastatic non-small cell lung cancer (NSCLC) (Duravelo-4)ESMO Open · 2026
13. Distinct H3K27 methylation states drive cellular responses to the histone demethylase inhibitor GSK-J4 in ovarian cancer cellsMolecular Cancer Therapeutics · 2026
14. PS5-09-23: A Phase 2 study of zelenectide pevedotin, a Bicycle Drug Conjugate, in patients with NECTIN4 amplified advanced breast cancer (Duravelo-3)Clinical Cancer Research · 2026
15. 2025 White Paper on Recent Issues in Bioanalysis: What is the Future of Bioanalytical LIMS? AI/ML Integration in Bioanalysis; Tear Sample Collection; Radiolabeled Mass Balance Studies; Chiral Assays; Bioanalysis of Antibody-Oligonucleotide & Bicycle Drug Conjugates ( PART 1A – Recommendations on Mass Spectrometry Assays, Chromatography, Sample Preparation and Regulated Bioanalysis Sampling, Validating, Analyzing & Reporting PART 1B – Regulatory Agencies’ Input on Regulated Bioanalysis/BMV)Bioanalysis · 2026
16. Utilizing Constrained Bicyclic Peptides for In Vitro DiagnosticsACS Nano · 2026
17. Bismuth BicyclesJournal of Peptide Science · 2026
18. Managing Drug-Drug Interactions Involving the Non-Prescription Opioid Loperamide Through Physiologically Based Pharmacokinetic Modeling.2026
19. From Cloudy to Clear: A Strategy to Resolve the Complex Structural Elucidation of Bicycle Drug Conjugate Zelenectide Pevedotin by NMRBioconjugate Chemistry · 2026
20. Small siphophage binding to an open state of the LptDE outer membrane lipopolysaccharide transloconProceedings of the National Academy of Sciences · 2025